126 related articles for article (PubMed ID: 37986292)
1. Suboptimal hepatobiliary phase image in gadoxetic acid-enhanced liver MRI for the evaluation of the HCC: Predictive factors.
Ryeom H; Chang Y; Park SY; Cho SH; Yeo B; Je H; Baek J
Medicine (Baltimore); 2023 Nov; 102(46):e36176. PubMed ID: 37986292
[TBL] [Abstract][Full Text] [Related]
2. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.
Pan J; Li W; Gu L; Liu C; Zhang K; Hong G
Eur Radiol; 2022 Nov; 32(11):7883-7895. PubMed ID: 35579711
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
[TBL] [Abstract][Full Text] [Related]
4. Computer-aided hepatocellular carcinoma detection on the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging using a convolutional neural network: Feasibility evaluation with multi-sequence data.
Cho Y; Han YE; Kim MJ; Park BJ; Sim KC; Sung DJ; Han NY; Park YS
Comput Methods Programs Biomed; 2022 Oct; 225():107032. PubMed ID: 35930863
[TBL] [Abstract][Full Text] [Related]
5. Total Bilirubin Level as a Predictor of Suboptimal Image Quality of the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI in Patients with Extrahepatic Bile Duct Cancer.
Hwang JA; Min JH; Kim SH; Choi SY; Lee JE; Moon JY
Korean J Radiol; 2022 Apr; 23(4):389-401. PubMed ID: 35029076
[TBL] [Abstract][Full Text] [Related]
6. Limitations of GD-EOB-DTPA-enhanced MRI: can clinical parameters predict suboptimal hepatobiliary phase?
Kobi M; Paroder V; Flusberg M; Rozenblit AM; Chernyak V
Clin Radiol; 2017 Jan; 72(1):55-62. PubMed ID: 27842889
[TBL] [Abstract][Full Text] [Related]
7. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.
Phongkitkarun S; Limsamutpetch K; Tannaphai P; Jatchavala J
World J Gastroenterol; 2013 Dec; 19(45):8357-65. PubMed ID: 24363528
[TBL] [Abstract][Full Text] [Related]
8. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.
Sun L; Mu L; Zhou J; Tang W; Zhang L; Xie S; Chen J; Wang J
Cancer Immunol Immunother; 2022 Jan; 71(1):25-38. PubMed ID: 33993366
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
[TBL] [Abstract][Full Text] [Related]
10. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
Kim SS; Kim SH; Song KD; Choi SY; Heo NH
J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
[TBL] [Abstract][Full Text] [Related]
11. Visualization Score of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging: The Effect on the Diagnostic Accuracy for Hepatocellular Carcinoma.
Heo S; Choi SH; Hong S; Kim DW
J Magn Reson Imaging; 2023 Mar; 57(3):941-949. PubMed ID: 35849038
[TBL] [Abstract][Full Text] [Related]
12. Determining the efficacy of functional liver imaging score (FLIS) obtained from gadoxetic acid-enhanced MRI in patients with chronic liver disease and liver cirrhosis: the relationship between Albumin-Bilirubin (ALBI) grade and FLIS.
Aslan S; Eryuruk U; Tasdemir MN; Cakir IM
Abdom Radiol (NY); 2022 Jul; 47(7):2325-2334. PubMed ID: 35672474
[TBL] [Abstract][Full Text] [Related]
13. T1 mapping combined with Gd-EOB-DTPA-enhanced magnetic resonance imaging in predicting the pathologic grading of hepatocellular carcinoma.
Chen CY; Chen J; Xia CC; Huang ZX; Song B
J Biol Regul Homeost Agents; 2017; 31(4):1029-1036. PubMed ID: 29254310
[TBL] [Abstract][Full Text] [Related]
14. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
[TBL] [Abstract][Full Text] [Related]
15. Gadoxetic acid-enhanced MRI as a predictor of recurrence of HCC after liver transplantation.
Lee S; Kim KW; Jeong WK; Kim MJ; Choi GH; Choi JS; Song GW; Lee SG
Eur Radiol; 2020 Feb; 30(2):987-995. PubMed ID: 31471754
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid.
Besa C; Lewis S; Pandharipande PV; Chhatwal J; Kamath A; Cooper N; Knight-Greenfield A; Babb JS; Boffetta P; Padron N; Sirlin CB; Taouli B
Abdom Radiol (NY); 2017 Jan; 42(1):179-190. PubMed ID: 27448609
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
[TBL] [Abstract][Full Text] [Related]
18. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma with central scar on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging.
Han SB; Kim YK; Min JH; Ha SY; Jeong WK; Lee WJ
Acta Radiol; 2018 Apr; 59(4):393-401. PubMed ID: 28760004
[TBL] [Abstract][Full Text] [Related]
20. Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC.
Lee DH; Lee JM; Yu MH; Hur BY; Yi NJ; Lee KW; Suh KS; Yoon JH; Kim YJ; Lee JH; Yu SJ; Han JK
Eur Radiol; 2019 Jun; 29(6):3122-3131. PubMed ID: 30643939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
